IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer

(3:3)

Final OS results of IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

(2:18)

Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer

(1:37)

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

(5:27)

IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer

(4:20)

IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

(48)

Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma

(2:57)

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

(2:30)

IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma

(7:21)

IMvigor130: a post-hoc analysis of atezolizumab monotherapy in urothelial carcinoma

(1:55)

IMvigor130: OS data for atezolizumab plus chemo versus chemo alone

(3:12)

Dr. Davis on IMvigor130 Trial in Metastatic Urothelial Cancer

(52)

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

(4:45)

Matthew Galsky, MD, tells us about the Phase 3 IMvigor130 study in advanced urothelial cancer

(1:10)

Key findings on atezolizumab for mUC from IMvigor130

(2:15)

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

(4:40)

IMvigor130 analysis stresses need to standardize PD-L1 expression assessment | Enrique Grande Pulido

(5:14)

Researcher comment: IMvigor130 trial of atezolizumab in advanced urothelial cancer | Enrique Grande

(1:43)

Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder Cancer

(54)

Adjuvant Immunotherapy: The IMVigor Trials - Bladder Cancer Video Library

(9:22)